Biomarkers of Prostate Cancer
- Identify unique proteins or peptides that are associated with prostate cancer by
comparing the proteomic or metabolomic analysis of serum, plasma, and urine from
patients with histological evidence of prostate cancer to those without prostate cancer
(after transrectal ultrasound prostatic biopsy).
- Collect seminal fluid from a subset of patients to test the hypothesis that the fluid
collected from the "target organ of injury" in prostate cancer will have a higher
signal of proteins/peptides that are different from those without cancer and may help
guide the identification of these differences in the serum, plasma, and urine.
OUTLINE: This is a pilot study.
Patients undergo collection of serum, plasma, and urine for biomarker/laboratory analysis.
Samples are examined by proteomic/metabolomic analysis (by mass spectrometry) and
immunoassays. Patients then undergo a transrectal ultrasonography prostatic biopsy.
PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.
Unique proteins or peptides associated with prostate cancer
Frank M. Torti, MD, MPH
Comprehensive Cancer Center of Wake Forest University
United States: Federal Government
|Wake Forest University Comprehensive Cancer Center||Winston-Salem, North Carolina 27157-1096|
|SurroMed Incorporated||Menlo Park, California 94025|